Z-c(=o)-o-y, Wherein Z Contains A Benzene Ring Patents (Class 514/532)
  • Patent number: 10588845
    Abstract: The present invention relates to toiletry products and more particularly to toiletry products that are manufactured in shaped forms. In particular, the invention relates to a bubble bath product, more particularly to a bubble bath product in shaped form, for example in shaped gel form. Certain embodiments of the present invention relate to formulations of bubble bath products which may be manufactured in shaped forms, for example in shaped gel form. Other embodiments relate to bubble bath products per se for example in shaped gel form. Other embodiments relate to a process for the manufacture of formulations of bubble bath product and of bubble bath products.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: March 17, 2020
    Assignee: Bubble Laboratiories Limited
    Inventor: Anthony T. Maleedy
  • Patent number: 10463614
    Abstract: The present invention discloses a butylphthalide intravenous emulsion for intravenous injection or infusion, containing butylphthalide or derivatives thereof as an active ingredient in an amount of 0.01˜50 wt % and an excipient in an amount of 50˜99.99 wt %, based on the total weight of the emulsion.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: November 5, 2019
    Assignee: SHIJIAZHUANG PHARMA GROUP NBP PHARMACEUTICAL CO.
    Inventors: Chunshun Zhao, Zhanqi Niu, Zhen Chen, Haibo Guo
  • Patent number: 10329249
    Abstract: The sulindac derivatives are compounds of the formula: wherein R is one of twenty-five substituted or unsubstituted phenyl substituents; and pharmaceutically acceptable salts thereof. The sulindac derivatives are synthesized by refluxing sulindac hydrazide with appropriately substituted benzaldehydes in the presence of ethanol and catalytic amounts of glacial acetic acid. The sulindac derivatives may be used as active ingredients in pharmaceutical compositions for the treatment of inflammation or inflammatory diseases. The sulindac derivatives may also be used as analgesic and/or gastric sparing agents.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: June 25, 2019
    Assignee: King Saud University
    Inventors: Mashooq Ahmad Bhat, Mohamed A. Al-Omar, Nawaf Abdulaziz Alsaif, Syed Hidayathulla
  • Patent number: 9956547
    Abstract: The invention relates to a method for preparing polyglycerol, comprising —providing a catalyst salt on a support, the catalyst salt having catalytic activity with respect to an etherification reaction of a polyol selected from the group of glycerol and oligoglycerols, —contacting the catalyst salt on the support with a fluid phase comprising a polyol selected from the group of glycerol and oligoglycerols, —and subjecting the polyol in the fluid phase to an etherification reaction in the presence of the catalyst salt, thereby forming the polyglycerol.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: May 1, 2018
    Assignees: Clariant International Ltd., Universiteit Utrecht Holding B.V.
    Inventors: Anton Kaiser, Bert Marc Weckhuysen, Dirk Leinweber, Fiona Kirby, Franz Xaver Scherl, Hans Joachim Metz, Pieter Cornelis Antonius Bruijnincx
  • Patent number: 9914692
    Abstract: Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric. Also provided is 4-phenyl-1-butyric acid prepared by such a process.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: March 13, 2018
    Assignee: Horizon Therapeutics, LLC
    Inventors: Huai-Chueh Chang, Steven S. Pfeiffer, Vasilios H. Iskos, Maki Uragami, Steven Weissman, Andrew Thompson
  • Patent number: 9707217
    Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: July 18, 2017
    Assignee: Osmotica Kereskedelmi es Szolgaltato KFT
    Inventors: Hernan D. Benedetti, Cristian R. Franco, Guido S. Bigatti, Joaquina Faour, Ana C. Pastini
  • Patent number: 9550716
    Abstract: Disclosed is a process for preparing a treprostinil salt. The process involves the step of dissolving treprostinil in a water-miscible organic solvent to form a treprostinil solution. The treprostinil solution is reacted with an aqueous basic solution containing an alkali metal cation to form treprostinil salt. Allowing crystallization of the treprostinil salt to take place, and then collecting the treprostinil salt formed.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: January 24, 2017
    Assignee: EON LABS, INC.
    Inventors: Walter Giust, Fabio Souza, Jan Oudenes, Boris Gorin, Elena Bejan
  • Patent number: 9376369
    Abstract: The present invention provides novel compounds with hypocholesteremic activity from crude Embilica officinialis (EO) extracts and methods of use. The invention also provides nutraceuticals.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: June 28, 2016
    Inventor: Subroto Chatterjee
  • Patent number: 9345660
    Abstract: A formulation to treat rheumatic disorders and related infections is provided. The formulation is a micro-emulsion including at one or more of an active ingredients. The active ingredient includes one or more of an essential oil mixed with an aqueous phase along with one or more of a surfactant and one or more of a co-surfactant. The co-surfactant is medicated by an extract of one or more of an herb.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: May 24, 2016
    Assignee: SUNEV PHARMA SOLUTION LIMITED
    Inventors: Manu Chaudhary, Vijay Naithani
  • Patent number: 9333210
    Abstract: A medicine composition contains vitamin D and metformin, wherein vitamin D comprises vitamin D2, vitamin D3, alphacalcidol, calcifediol, calcitriol, and dihydrotachysterol. The composition can be used in the preparation of a medicine for treating and/or preventing a polyp and cancer in large intestine.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: May 10, 2016
    Assignee: GUANGDONG TAIHE MEDICINE SCIENCE & TECHNOLOGY CO., LTD
    Inventor: Fulin Fan
  • Patent number: 9144549
    Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 29, 2015
    Assignee: ALZA CORPORATION
    Inventors: Suneel K. Gupta, Diane R Guinta, Carol A. Christopher, Samuel R. Saks, Lawrence G. Hamel
  • Patent number: 9119799
    Abstract: Transdermal compositions are provided. Aspects of the transdermal compositions include: an active agent layer and a conversion layer, where the conversion layer includes a weak base and, optionally, a carboxylated component. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: September 1, 2015
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Richard Hamlin, Jianye Wen
  • Patent number: 9029416
    Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: May 12, 2015
    Assignee: Alza Corporation
    Inventors: Andrew C. Lam, Padmaja Shivanand, Atul D. Ayer, Zahedeh Hatamkhany, Suneel K. Gupta, Diane R. Guinta, Carol A. Christopher, Samuel R. Saks, Lawrence G. Hamel, Jeri D. Wright, Richard G. Weyers
  • Publication number: 20150125407
    Abstract: The present invention relates to vesicular formulations for use in the topical administration of a biologically active agent, methods of administering a biologically active agent, a combined preparation comprising a vesicular formulation and a kit comprising a vesicular formulation.
    Type: Application
    Filed: May 10, 2013
    Publication date: May 7, 2015
    Applicant: Sequessome Technology Holdings Ltd
    Inventors: William Henry, Richard Wolf Garraway, John Mayo
  • Publication number: 20150119461
    Abstract: The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPAR? modulation such as diabetes.
    Type: Application
    Filed: January 9, 2015
    Publication date: April 30, 2015
    Inventors: Veera KONDA, Jan URBAN, Anuradha DESAI, Clinton J. DAHLBERG, Brian J. CARROLL
  • Patent number: 9000038
    Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: April 7, 2015
    Assignee: ALZA Corporation
    Inventors: Andrew C. Lam, Padmaja Shivanand, Atul D Ayer, Zahedeh Hatamkhany, Richard G Weyers, Suneel K. Gupta, Diane R Guinta, Carol A. Christopher, Samuel R. Saks, Lawrence G. Hamel, Jeri D. Wright
  • Publication number: 20150094343
    Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.
    Type: Application
    Filed: June 4, 2014
    Publication date: April 2, 2015
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Waldemar PRIEBE, Izabela FOKT, Slawomir SZYMANSKI, Timothy MADDEN, Jeffrey MYERS, Charles CONRAD
  • Patent number: 8993621
    Abstract: This invention relates to caffeic acid derivatives and improving viability of neuronal cells by contacting neuronal cells by caffeic acid derivatives as shown in the specification.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: March 31, 2015
    Assignee: Chemigen, Inc.
    Inventors: Junyi Liu, Yansheng Du
  • Patent number: 8980869
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: March 17, 2015
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventor: Pedro Cuevas Sànchez
  • Patent number: 8980867
    Abstract: Suggested are biocide compositions, comprising (a) Alkoxylated oligoglycerol esters; (b) Biocides and optionally (c) Oil components or co-solvents and/or (d) Emulsifiers. The compositions show excellent adjuvant properties.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: March 17, 2015
    Assignee: Cognis IP Management GmbH
    Inventors: Hans-Georg Mainx, Sandra Mack, Ingo Fleute-Schlachter
  • Publication number: 20150073047
    Abstract: Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation.
    Type: Application
    Filed: August 1, 2014
    Publication date: March 12, 2015
    Inventor: Nicos A. Petasis
  • Patent number: 8968710
    Abstract: A topical anesthetic is provided containing about 3 wt % to 10 wt % tetracaine in a vehicle suitable for administration to the skin or mucosa. The vehicle for transporting the tetracaine includes a water soluble mucoadhesive or a combination of mucoadhesives such as a high molecular weight poly(ethylene oxide) homopolymer and a cellulose polymer. The vehicle also includes propylene glycol. The tetracaine is ground into a powder and is suspended in a plasticized hydrocarbon gel which completes the vehicle.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: March 3, 2015
    Inventors: Alan J. Wickenhauser, Stephen E. Peipert
  • Patent number: 8956589
    Abstract: Disclosed are a curcumin derivative or a salt thereof, which contains a fluorine atom, represented by formula (I): (wherein R1a and R1b are each independently a hydrogen atom, alkyl, acetyl, or methoxycarbonyl; R2s are each independently a fluorine atom, CHF2—, CF3—, CHF2O—, or CF3O—; R3s are each independently a hydrogen atom or a fluorine atom; A is alkyl, cyano, carboxyl, alkoxycarbonyl, or R4—(CH2)m—; R4 is hydroxy, carboxy, cyano, acetyloxy, alkoxycarbonyl, alkoxyalkoxy, hydroxyalkoxy, or CONR5R6; R5 and R6 are each independently a hydrogen atom or alkyl; and m is an integer from 1 to 5), and a diagnostic imaging agent for diagnosing a disease in which an amyloid ? peptide aggregate accumulates, the diagnostic imaging agent containing a compound having a 1,3-dicarbonyl structure, wherein the compound exists in a keto form and an enol form, and the keto form and the enol form have different affinities, respectively, to the amyloid ? peptide aggregate.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: February 17, 2015
    Assignee: Shiga University of Medical Science
    Inventors: Ikuo Tooyama, Hiroyasu Taguchi, Shigehiro Morikawa, Makoto Urushitani, Daijiro Yanagisawa, Tomone Nagae, Nobuaki Shirai, Koichi Hirao, Masanari Kato, Hirohiko Kimura, Takashi Okada
  • Patent number: 8933121
    Abstract: The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-?), Interleukin-6 (IL-6) and Interleukin-1 (IL-1?).
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: January 13, 2015
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Anjali Pandey
  • Patent number: 8912186
    Abstract: The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: December 16, 2014
    Assignee: Universitaet des Saarlandes
    Inventors: Matthias Engel, Wolfgang Fröhner, Adriane Stroba, Ricardo M. Biondi
  • Patent number: 8912171
    Abstract: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: December 16, 2014
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventor: Pedro Cuevas Sànchez
  • Patent number: 8901169
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: December 2, 2014
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Erik Fenster, Melissa Fleury, Adam D. Hughes
  • Patent number: 8877234
    Abstract: The invention relates to clear, liquid preservatives, which contain a) one or several 1-hydroxy-4-methyl-6-alkyl-2(1H)-pyridones and/or one or several salts thereof, wherein alkyl represents a linear, branched or cyclic alkyl group having 1-12 carbon atoms, and b) one or several alcohols containing one or several aromatic groups.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: November 4, 2014
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Waltraud Simsch, {dot over (P)}eter Klug, Sonja Klein
  • Patent number: 8877732
    Abstract: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: November 4, 2014
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Rudolf A. Baumgartner
  • Publication number: 20140314699
    Abstract: The present invention concerns a compound of formula wherein R represents a hydrogen atom or a C1-2 alkyl or alkoxyl group; each R1, R2 or R3 represents a hydrogen atom or a methyl or ethyl group; and X represents a CHO, COOR4 or CN group, R4 being a methyl or ethyl group; and at least one of said R, R1 or R2 represents a group containing at least one carbon atom; and it use as perfuming ingredient, for instance to impart odor notes of the floral and/or anis type.
    Type: Application
    Filed: July 3, 2014
    Publication date: October 23, 2014
    Applicant: FIRMENICH SA
    Inventor: Robert MORETTI
  • Patent number: 8846742
    Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: September 30, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
  • Publication number: 20140275247
    Abstract: The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: A.T. Resolve Sarl
    Inventors: Per Gjorstrup, C. Eric Schwartz
  • Publication number: 20140249192
    Abstract: The present invention provides compounds, that are N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfonamido)propyl)benzyl)pyrrolidin-2-yl)oxazole-4-carboxamide wherein the 5 substituent is selected from the group consisting of halo and alkyloxy radicals. The compound may be represented by the following formula wherein R1 is selected from the group consisting of CO2R7 and CON(R7)SO2R7 wherein R1, R2, R3, R4, and R7 are as defined in the specification. The compounds may be administered to treat DP1, FP, EP1, EP3, TP and/or EP4 receptor mediated diseases or conditions.
    Type: Application
    Filed: February 12, 2014
    Publication date: September 4, 2014
    Applicant: Allergan, Inc.
    Inventors: Jose L. Martos, William R. Carling, David F. Woodward, Jenny W. Wang, Jussi J. Kangasmetsa
  • Publication number: 20140249219
    Abstract: The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-?), Interleukin-6 (IL-6) and Interleukin-1 (IL-1?).
    Type: Application
    Filed: May 9, 2014
    Publication date: September 4, 2014
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Anju Majeed, Bani Sarang, Anjali Pandey
  • Patent number: 8815836
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: August 26, 2014
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Pedro Cueva Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Patent number: 8802881
    Abstract: Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: August 12, 2014
    Assignee: University of Southern California
    Inventor: Nicos A. Petasis
  • Publication number: 20140221426
    Abstract: Presystemic metabolism in intestine of bioactives such as phenylephrine is avoided by administering a subject (human or animal) the bioactive (e.g., phenylephrine) in combination with one or more inhibitors of sulfation (e.g., sulfotransferase enzymes aka SULTs). This can also be enhanced be co-administering inhibitors of monoamine oxidases aka, MAOs, and uridine diphosphate glucoronysl transferases, aka UGTs. Preferably the inhibitors are GRAS compounds. The one or more inhibitor compounds inhibit the enzymes responsible for rapid presystemic metabolism, thus allowing the bioactives (e.g., phenylephrine) to be more readily absorbed intact into the circulatory system.
    Type: Application
    Filed: September 27, 2012
    Publication date: August 7, 2014
    Inventors: Phillip M. Gerk, William H. Barr, Joseph K. Ritter
  • Patent number: 8791159
    Abstract: A compound having an ability to bind to an SIP receptor and represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like: wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and R1 is a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and R1 is a substituent, and wherein m is 2 or more, R1s are the same or different.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: July 29, 2014
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Shinji Nakade, Hirotaka Mizuno, Takeji Ono, Masashi Minami, Hiroshi Saga, Hiroshi Hagiya, Takaki Komiya, Hiromu Habashita, Haruto Kurata, Kazuhiro Ohtsuki, Kensuke Kusumi
  • Patent number: 8784873
    Abstract: The invention provides a method of changing a ratio of 68 to 64 kDa protein of MRJP3 in a royal jelly, a method of producing a royal jelly comprising MRJP3 having a changed ratio of 68 to 64 kDa protein relative to a control royal jelly and the royal jelly produced thereform. Also provided is a method of promoting the growth of the larva of a queen bee comprising feeding the larva of the queen bee a royal jelly of the invention. Further provided is a method of producing bee larva, pupa and queen bees with sizes larger than normal.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: July 22, 2014
    Assignee: Naturewise Biotech & Medicals Corporation
    Inventors: Chung-Yang Huang, Chia-Nan Chen, Wei-Jung Chen, Wei-Jan Huang, Li-Ling Chi
  • Patent number: 8765809
    Abstract: A compound represented by the following formula (I?) wherein X1 is a methylene group, an ethylene group, a trimethylene group or a vinylene group, X2 is a divalent group represented by the following formula A or B, Y is an ethylene group or a vinylene group, m and n are each an integer of 0 to 7, which satisfy m+n=0 to 8, R1 and R2 are each independently a hydrogen atom, a methyl group or an ethyl group, provided that when X1 is a methylene group, then X2 is not a divalent group represented by the formula A, and when X1 is a vinylene group, then X2 is not a divalent group represented by the formula A. The compound is a stable capsinoid derivative, and is useful as an active ingredient of an external blood circulation enhancer or a cosmetic composition, a pharmaceutical composition, or a food composition.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: July 1, 2014
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yusuke Amino, Yoshinobu Takino
  • Patent number: 8759327
    Abstract: The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.
    Type: Grant
    Filed: April 16, 2008
    Date of Patent: June 24, 2014
    Assignees: The Regents of the University of Michigan, University of Maryland, Baltimore, Eastern Michigan University
    Inventors: Daniel A. Lawrence, Dudley Strickland, Jacqueline Cale, Enming J. Su, Cory Emal, Mark Warnock
  • Patent number: 8748491
    Abstract: The present invention refers to tricyclic diterpenes and their derivatives of the formulae (I) and (II), wherein R1 is hydrogen or C1-6-alkyl; R2 is hydroxy, C3-5-acyloxy, hydroxymethyl, 1,3-dihydroxypropyl or C1-6-alkyl; R3 and R4 independently from each other are hydrogen, hydroxy, hydroxymethyl, C1-5-acyloxy or C1-6-alkoxy; R5 is C1-6-alkyl, hydroxymethyl carboxy or methoxycarbonyl; R9 is hydrogen, hydroxymethyl, methoxy, oxo or C1-5-acyloxy; R10 is hydrogen, or R5 and R9 taken together are —CH2—O— or —O—CH2—; or R5 and R10 taken together are —CO—O—, —O—CO—, —CH2—O— or —O—CH2—; R6 is hydrogen, or R5 and R6 together to form a bond; R7 and R8 independently from each other are C1-6-alkyl, carboxy, x-hydroxy-Cx-alkyl (with x being an integer from 1 to 6), or C1-6-alkoxycarbonyl with the proviso that at least one of R7 and R8 is C1-6-alkyl; R11 and R12 are both hydrogen or R11 and R12 together are oxo, with the further proviso for formula (I) that if R2 is hydroxy R1 is C1-6-alkyl, for use as medicaments for th
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: June 10, 2014
    Assignee: DSM IP Assets B.V.
    Inventors: Antione De Saizieu, Ann Fowler, Regina Goralczyk, Claus Kilpert, Goede Schueler, Christof Wehrli
  • Patent number: 8748487
    Abstract: Disclosed is a raw material for cosmetic preparations having excellent gloss imparting properties and oxidation stability. Also disclosed is a cosmetic preparation having excellent gloss and feeling of use. The raw material for cosmetic preparations contains an ester compound of (A) benzoic acid, (B) an alcohol selected from the group consisting of neopentyl glycol, dineopentyl glycol, trineopentyl glycol, trimethylolpropane, ditrimethylolpropane, tritrimethylolpropane, dipentaerythritol and tripentaerythritol, and (C) a fatty acid having 3-28 carbon atoms and/or a hydroxycarboxylic acid having 3-28 carbon atoms. The cosmetic preparation contains this raw material for cosmetic preparations.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: June 10, 2014
    Assignee: The Nisshin Oillio Group, Ltd.
    Inventor: Keiji Yasuno
  • Publication number: 20140140931
    Abstract: This invention relates to antioxidant, neuroprotective and antineoplastic nanoparticles comprising a therapeutic agent on an amphiphilic spacer or an amphiphilic polymer. Methods of synthesizing the antioxidant derivatives of camptothecin and anti-oxidant derivatives of camptothecin analogs, NSAIDs and statins, spontaneous emulsification or nanoprecipitation thereof to produce antioxidant, neuroprotective and anti-neoplastic nanoparticles comprising a therapeutic agent on an amphiphilic spacer or an amphiphilic polymer and their use in treating cancerous diseases are also provided. A further aspect of this invention is the use of these neuroprotective and anti-neoplastic nanoparticles for the preparation of delivery devices of other pharmaceuticals and/or drugs.
    Type: Application
    Filed: July 27, 2012
    Publication date: May 22, 2014
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: John S. Yu, Bong Seop Lee
  • Patent number: 8729122
    Abstract: The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of pharmaceutical and/or nutraceutical use.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: May 20, 2014
    Assignee: Valent BioSciences Corporation
    Inventors: Maria Pilar Herrero, Warren E. Shafer
  • Publication number: 20140127316
    Abstract: Methods for treating a subject with cancer using a combined therapeutic regimen comprising administering propolis or caffeic acid phenethyl ester (CAPE) in conjunction with other cancer therapeutics are described herein. More particularly, methods for treating subjects with breast cancer using the combined therapeutic regimen are embodied herein. The present methods are particularly useful for treating cancer patients (e.g., breast cancer patients) who are refractory to or who have become refractory to the cancer therapeutic/s used in combination with propolis or CAPE. Propolis or CAPE for use in a combined treatment with other cancer therapeutics for treating cancer patients and compositions comprising propolis or CAPE and other cancer therapeutics are also encompassed herein wherein the ability of propolis or CAPE to act as a histone deacetylase (HDAC) inhibitor is used to advantage.
    Type: Application
    Filed: May 21, 2012
    Publication date: May 8, 2014
    Inventors: Coral Omene, Owen O'Connor, Krystyna Frenkel
  • Publication number: 20140107166
    Abstract: The present invention provides novel compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone deacetylase activity (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, hair loss, etc.) comprising administering a therapeutically effective amount of a compound of the invention to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.
    Type: Application
    Filed: February 13, 2012
    Publication date: April 17, 2014
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Ralph Mazitschek, James E. Bradner, Melissa Grachan Harman
  • Patent number: 8691868
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: April 8, 2014
    Assignee: Theravance, Inc.
    Inventors: Adam D. Hughes, Erik Fenster, Melissa Fleury, Roland Gendron, Edmund J. Moran
  • Patent number: 8685887
    Abstract: The present application relates to surfactant compositions comprising a) at least one phosphated arylphenol alkoxylate surfactant having an average degree of alkoxylation of from 4-8; and b) at least one alkylamine alkoxylate surfactant having an average degree of alkoxylation of from 2-12 and to the use of these compositions in pesticide formulations comprising solid or encapsulated pesticidally active ingredients or formulation aids and methods for improving the re-suspension properties of pesticide suspensions.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: April 1, 2014
    Assignee: Syngenta Crop Protection LLC
    Inventors: Randall Charles Cush, Sarah Beth Cush, Michael James Hopkinson, Jason Keiper
  • Patent number: 8680125
    Abstract: Described herein are methods for treating inflammatory disorders. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: March 25, 2014
    Assignee: Luna Innovations Incorporated
    Inventors: Christopher L. Kepley, Robert P. Lenk, Stephen R. Wilson, Zhiguo Zhou, Darren K. MacFarland